Sanofi (NYSE:SNY) Scheduled to Post Earnings on Monday
Sanofi (NYSE:SNY) is scheduled to be announcing its earnings results before the market opens on Monday, July 31st. Analysts expect the company to announce earnings of $0.75 per share for the quarter.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Friday, April 28th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.03. Sanofi had a return on equity of 25.89% and a net margin of 26.55%. The company had revenue of $8.65 billion for the quarter, compared to analyst estimates of $8.40 billion. The company’s revenue was up 1.2% on a year-over-year basis. On average, analysts expect Sanofi to post $3.2 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.
Shares of Sanofi (NYSE:SNY) traded down 0.198% during trading on Thursday, hitting $47.925. The stock had a trading volume of 911,373 shares. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The firm’s 50 day moving average is $48.17 and its 200 day moving average is $45.59. The company has a market cap of $121.03 billion, a PE ratio of 11.555 and a beta of 0.89.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/07/27/sanofi-nysesny-scheduled-to-post-earnings-on-monday.html.
A number of equities research analysts recently issued reports on SNY shares. Zacks Investment Research downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. J P Morgan Chase & Co reiterated a “sell” rating on shares of Sanofi in a research report on Wednesday, April 5th. HSBC Holdings plc downgraded Sanofi from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Finally, BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $67.67.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.